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MaTranscatheter aortic valve replacement (TAVR) with the use of the self-expandable Revalving system is an accepted
alternative to surgical replacement for severe, symptomatic aortic stenosis in high-risk or inoperable patients. Intra-
procedural imaging relies on ﬂuoroscopic guidance, with echocardiographic imaging used as a supportive imaging
modality. Intraprocedural transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) offer real-
time imaging guidance throughout the procedure and may contribute to improving procedural results. Registries suggest
that TAVR may be performed in lower-surgical-risk patients with equal outcomes to high-risk patients with ongoing
randomized trials comparing these results with surgical outcomes. Understanding the utility of echocardiographic
imaging in diagnosing or preventing complications may be particularly important as we move toward these lower-risk
patient populations. This imaging compendium is intended to be a comprehensive compilation of intraprocedural
complications imaged by intraprocedural echocardiography. (J Am Coll Cardiol Img 2015;8:319–36) © 2015 by the
American College of Cardiology Foundation.M ultiple complications of transcatheteraortic valve replacement (TAVR) withthe self-expanding valve system (Core-
Valve, Medtronic Inc., Minneapolis, Minnesota) have
been reported (1–7). These include malpositioning,
valve migration/embolization, coronary ischemia
caused by compromise of one or both coronary ostia,
or aortic injury such as annular rupture or other rea-
sons for conversion to open surgery. Initial implanta-
tions of the self-expanding valve both in Europe and
the United States were performed with the use of gen-
eral anesthesia and transesophageal echocardiogra-
phy (TEE) imaging; however, as investigators have
become more accustomed to implanting this valve
under ﬂuoroscopic guidance, many centers have
moved toward implanting the device with minimal
echocardiographic support. Although further study
comparing the beneﬁts of intraprocedural echocar-
diographic guidance should be performed, the risks
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investigators who suggest that TEE is not a necessary
part of the procedure (11,12). These investigators state
that the primary reason to avoid the use of TEE is the
risk of general anesthesia; however, general anes-
thesia carries a very low risk (10) that may be out-
weighed by the early diagnosis of complications
associated with this procedure. As we perform TAVR
in lower-risk groups, any delay in diagnosis may
adversely affect outcomes. In addition, although
TEE is typically performed under general anesthesia,
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conscious sedation (9). There seem to be limited bar-
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transthoracic echocardiography (TTE) guidance.
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ABBR EV I A T I ON S
AND ACRONYMS
3DE = 3-dimensional
echocardiography
BAV = balloon aortic
valvuloplasty
LV = left ventricle/ventricular
PAR = paravalvular aortic
regurgitation
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
THV = transcatheter
heart valve
TTE = transthoracic
echocardiography
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320placement of a TEE probe; this thus risks a
delayed diagnosis of possibly reversible com-
plications. The purpose of this article is to
give echocardiographers with less experience
exposure to the imaging of complications of
the self-expanding transcatheter heart valve
(THV) that are rarely encountered clinically.
BALLOON AORTIC VALVULOPLASTY
Balloon aortic valvuloplasty (BAV) is often
used before valve implantation to increase
cusp mobility and improve introduction and
positioning of the THV. In a single-site study
of 262 patients (13), serious adverse events
occurred in 47 patients (15.6%), intra-
procedural death in 5 (1.6%), stroke in 6(1.99%), coronary occlusion in 2 (0.66%), severe aortic
regurgitation in 4 (1.3%), resuscitation/cardioversion
in 5 (1.6%), tamponade in 1 (0.33%), and permanent
pacemaker in 3 (0.99%). Many of these complications
can be diagnosed rapidly with the use of intra-
procedural TEE. Figure 1 (Online Video 1) is an
example of an avulsed aortic cusp, causing acute,
severe aortic regurgitation and resulting in signiﬁ-
cant hypotension. The treatment of choice is im-
mediate valve implantation, which, in this case,
resulted in recovery of hemodynamic stability. Acute
disruption of calciﬁc nodules may also occur; inSEE PAGE 337Figure 2 (Online Video 2), mobile debris was noted
immediately after BAV with subsequent acute left
ventricular (LV) hypokinesis and resulting hypo-
tension requiring cardiopulmonary resuscitation; a
coronary occlusion from embolic calcium was the
presumed etiology. The self-expanding valve was
implanted emergently followed by a left main coro-
nary artery stent; however, distal left main turbu-
lence continued to be seen with apical hypokinesis.
BAV in patients receiving a self-expanding valve
has been associated with an increased rate of con-
duction defect (14) as well as pacemaker implantation
(15). Recent randomized trials of self-expanding valve
implantation (7,16) used an under-sized balloon
(relative to the measured annulus) for BAV before
self-expanding valve implantation to reduce the risk
of this complication. Others have advocated im-
planting the self-expanding valve without pre-
implant BAV (17,18).
MALPOSITIONING
The optimal positioning of the self-expanding valve
has evolved over time, as the complications ofhigh (too aortic relative to the annulus) or low
(too ventricular relative to the annulus) have been
described. Initial implantation recommendations
positioned the inﬂow (ventricular) edge of the THV
10 to 12 mm below the virtual annulus; however,
recent recommendations are to implant the valve
between no less than 4 mm and no more than 10
mm below the annulus. Low implantation may
result in impingement on the mitral apparatus,
resulting in acute and often poorly tolerated mitral
insufﬁciency (19,20) as well as severe paravalvular
aortic regurgitation (PAR) (21,22). Figure 3 shows a
very low implantation of a 31-mm valve, resulting in
both severe PAR and severe mitral regurgitation
(Figures 3A and 3B, Online Video 3). Low positioning
of the self-expanding valve has also been associated
with impingement of the atrioventricular (AV) node
causing bradyarrhythmias or bundle-branch block (23)
necessitating permanent pacemaker implantation
(14,24,25). Predictors of pacemaker implantation
include a low position (>4 mm depth below the
annulus) (26) and signiﬁcant over-sizing or the use of
a large prosthesis (27). Recent trials (28,29) report a
lower rate of pacemaker requirement (20% to 23%)
compared with multiple other registries and trials
reporting rates of 26% to 38% (25,30,31), which may be
related to a procedural change in implantation depth.
High implantation position may be associated with
signiﬁcant aortic regurgitation (Figure 4), valve
embolization (Figure 5), coronary obstruction, or
aortic dissection. Embolization or dislocation of
the valve prosthesis into the aorta has been associ-
ated with poor outcomes (32,33). Geisbusch et al. (33)
reported an overall 30-day mortality rate of
21.5% in the dislocation group and 9.9% in patients
without dislocation (p ¼ 0.024). Coronary ischemia,
stroke, and renal failure occurred more frequently in
patients with dislocation, whereas pacemaker de-
pendency did not differ signiﬁcantly between the
groups (28).
Avoiding malpositioning with the current self-
expandable valve system requires a slow, controlled
deployment of the valve. Most malpositioning occurs
in the setting of deploying the valve too rapidly and
failing to account for slight operator-independent
changes in valve position that occur as the edges of
the stented frame are exposed and come in contact
with the native anatomy. Although ﬂuoroscopy is the
primary imaging modality for valve deployment,
echocardiography may be helpful in real-time imag-
ing of these subtle changes in valve position during
gradual release of the valve, giving the intervention-
alist a clearer picture of THV interaction with native
structures.
FIGURE 1 Complications of Balloon Aortic Valvuloplasty: Avulsed Coronary Cusp
Immediately after balloon aortic valvuloplasty (A, simultaneous multiplane image), an avulsed noncoronary aortic cusp (yellow arrow) is
imaged from the long-axis view (B) (Online Video 1) as well as the short-axis view (C). This traumatic injury to the aortic valve was accompanied
by acute severe aortic regurgitation (D, red arrows, simultaneous multiplane image). Immediate deployment of a 29-mm valve resulted in
recovery of hemodynamic stability, with no paravalvular regurgitation.
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321REGIONAL WALL MOTION ABNORMALITIES
Acute regional wall motion abnormalities should pre-
cipitate a rapid assessment for possible etiologies,
including: 1) new bundle-branch block; 2) initiation of
lower threshold pacemaker rate (of a previously
implanted electronic right ventricular apical pace-
maker); 3) loculated hemopericardium with focal LVcompression; and 4) coronary artery occlusion by
native leaﬂets or calciﬁc emboli (Figure 2). A recent
meta-analysis of 18 studies found that the factors
associated with coronary obstruction after TAVR
include female sex, small aortic root diameter (mean
diameter ¼ 27.8  2.8 mm) and low-lying coronary ar-
tery (mean height ¼ 10.3  1.6 mm) (4). Of note, the
anatomic requirements for valve implantation include
FIGURE 2 Complications of Balloon Aortic Valvuloplasty: Coronary Artery Occlusion
A routine balloon aortic valvuloplasty (BAV) was performed before transcatheter aortic valve replacement (TAVR) (A). Immediately after BAV,
mobile debris (B, arrows) (Online Video 2) are noted. Shortly afterward, acute left ventricular dysfunction and resulting hypotension required
cardiopulmonary resuscitation and emergency implantation of a self-expanding valve. After TAVR, a left main coronary artery stent was placed
(C, red arrow); however, distal left main turbulence (D, red arrow) with apical hypokinesis was observed.
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322a sinus of Valsalva width of $27 mm for the 26-mm
valve and $29 mm for the 29- and 31-mm valves
(34), which may explain the lower incidence of coro-
nary occlusion with the self-expanding valve in the
meta-analysis.
More recently, TAVR with the self-expanding
valve has been performed without strict aortic size
or angulation criteria, and coronary occlusion may
become a more frequent complication, probably
related to the relative size of the THV at the level of
the coronary ostia. The nonconstrained portion
(inﬂow or ventricular end) of the valve is a wider
portion of the nitinol frame than the constrained
portion (approximate leaﬂet coaptation point); it will
push the native cusps further out into the sinuses
and risks occlusion of the coronaries. Thus, positions
typically too high may result in a wider portion of
the stented frame forcing the native cusp into
the oriﬁce of the coronaries. Some authors havesuggested that placement of the valve 1 to 2 mm
lower (deeper into the ventricle) results in the con-
strained portion of the valve being positioned at the
level of the coronary ostia; however, this might in-
crease the risk of conduction abnormalities (35). Pa-
tients with occluded coronaries typically present
with severe persistent hypotension immediately af-
ter valve implantation with regional wall motion
abnormalities (Figure 6, Online Video 4). Less
commonly, symptoms of coronary occlusion occur
within the ﬁrst few hours or within the ﬁrst 2 days
after the procedure. Coronary obstruction occurred
more frequently in the left coronary artery (83.3%).
Whereas successful coronary stenting may be
accomplished with acute improvement in LV func-
tion, reperfusion may be challenging, particularly if
the occlusion is the result of a high deployment in
which access to the ostium may be limited by the
transcatheter valve elements.
FIGURE 3 Complications of Malpositioning: Low (Too Ventricular) Position
As seen in these deep transgastric images, the patient’s 31-mmvalve ﬁnal positionwas low after implantation (A) (Online Video 3), resulting in not
only severe paravalvular regurgitation (red arrows) but also signiﬁcantmitral regurgitation (B, green arrow). Despite the use of a snare to pull the
valve into a more aortic position and post-dilation, the valve migrated back into the ventricle over the ensuing 12 h. The valve was then again
snared (C) and a balloon-expandable valve was positioned and deployed (D) to hold the valve in position, relieving not only the paravalvular
regurgitation but also the mitral regurgitation. After balloon-expandable valve implantation within the self-expanding valve, there was no
signiﬁcant paravalvular regurgitation (E).
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323PARAVALVULAR REGURGITATION
Although a recent report of the UK TAVI Registry
suggests that outcomes related to PAR may not be as
signiﬁcant for the self-expanding valve as the balloon-
expandable valve (36), numerous other studies of the
self-expanding valve suggest a higher mortality rate
in the setting of signiﬁcant PAR (37–40). Ussia et al.
(41) reported that severe PAR after self-expanding
valve implantation is commonly caused by under-
expansion (44%); however, malpositioning also
occurred with deployment too low (Figure 7) more
commonly the etiology of PAR (22.2%) than deploy-
ment too high (5.5%) (Figure 8). Studies suggest
that implantation depths of more than 10 to 15 mm
are associated with increased PAR (42,43). Reposi-
tioning of a low implant can often be corrected by
snaring the device with a “gooseneck” catheter (44)(Figure 3). A second implant (valve-in-valve bailout
procedure) is reserved for ineffective repositioning
(Figures 7 and 8) (45,46). In the CHOICE (Comparison
of Balloon-Expandable vs Self-expandable Valves
in Patients Undergoing Transcatheter Aortic Valve
Replacement) trial, transcatheter valve-in valve
bailout was performed in 5.8% of patients receiving
a self-expanding valve (compared with 0.8% of
patients receiving a balloon-expandable valve) (25).
The second method for intraprocedural treatment
of PAR is post-dilation. A risk-beneﬁt analysis must
be performed when considering post-dilation for
PAR. The risks of post-dilation include aortic trauma,
annular rupture (see Landing Zone Trauma below),
migration of the transcatheter valve, and coronary
obstruction. Although the need for post-dilation
with the self-expanding valve may be high—up to
49% of patients in some trials (25)—Barbanti et al.
FIGURE 4 Complications of Malpositioning: High (Too Aortic) Position
An 88-year-old man with severe symptomatic aortic stenosis had a high-positioned valve implantation (A, green arrow) (indicates the proximal
ends of the transcatheter heart valve). After a delay of 15 s, the device exhibited superior migration (B, red arrows) with immediate devel-
opment of severe paravalvular aortic regurgitation (C, yellow arrows).
FIGURE 5 Migration of the Transcatheter Valve During Deployment
Although the position of the valve during implantation (before full deployment) appeared to be low (A) (transcatheter heart valve [THV]
between red arrows), the ﬁnal position on release of the valve was high. Soon after release, imaging of the aortic valve (B) showed no evidence
of the self-expanding valve, and subsequent ﬂuoroscopy of the abdominal aorta identiﬁed the location of the valve (C) (THV between
red arrows).
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FIGURE 6 Complications Imaged by Transthoracic Imaging
In a 78-year-old patient with severe chronic obstructive pulmonary disease, imaging was performed with transthoracic echocardiography under
conscious sedation. Although there was no complication during the procedure (A) (normal apex indicated by red arrows), within 10 min of
the implant there was apical dyskinesis (B) (dilated apex indicated by red arrows) (Online Video 4). An acute left coronary occlusion was
suspected from either progressive nitinol expansion or migration of the valve superiorly. As the transesophageal echocardiography probe was
being passed, the interventionalist snared the valve and positioned it into the ascending aorta (C, yellow arrows), relieving the coronary
obstruction. Left ventricular function returned to normal. The native effective oriﬁce area after this transient valve implantation was 1.2 cm2,
and no further intervention was performed.
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325(47) showed that post-dilation of the self-expanding
THV may be performed for under-expansion with
low complication rates and no apparent risk for
neurological events. However the efﬁcacy of post-
dilation for the valve may be low, only 37% improve
to less than mild PAR.
Part of the decision-making process about post-
dilation relies on assessing the severity and etiology
of PAR. The detection of PAR for the self-expanding
valve is nuanced, with some studies suggesting
that echocardiography underestimates the severity
compared with cardiac magnetic resonance (25). Thehigher incidence of PAR compared with the balloon-
expandable valve reported in some, but not all, se-
ries, (7–21,25) may be related to the valve design and
multidirectional, eccentric jets that can be seen.
Because the lowest 4 mm of the valve has an inter-
mittent instead of continuous skirt, implanting the
valve too high risks PAR, not only around the lowest
border of the THV but also between the 4 mm of
uncovered cells. Thus, the ideal position of the valve
is probably between 5 to 10 mm below the annulus,
positioning the continuous portion of the skirt below
the annulus. Importantly, if positioning has been
FIGURE 7 Transcatheter Valve–in–Transcatheter Valve Salvage for Low (Ventricular) Positioned Valve
A 62-year-old woman with multiple comorbidities and a bicuspid valve underwent transcatheter aortic valve replacement with the use of
a 31-mm valve. (A) Baseline simultaneous multiplane transesophageal echocardiographic image of the valve, with color Doppler showing
the single midline commissure in systole of the bicuspid aortic valve (B, yellow arrow). During positioning, the valve unexpectedly
moved apically, resulting in the proximal end of the transcatheter heart valve within the left ventricle (C, red arrows). Three-dimensional
color Doppler revealed severe regurgitation (D, blue arrows). A second valve was immediately deployed superior (aortic) to the ﬁrst
valve (E) (red arrows are the ﬁrst valve and green arrows are the second valve); trivial paravalvular regurgitation is seen (F).
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326optimal, the regurgitation that is seen immediately
after deployment may resolve spontaneously over the
next 10 to 15 min. A post-dilation after this time
should be considered when: 1) there is well-imaged
malapposition of the stented valve with the native
structures at the site of PAR; and 2) when the shape of
the valve indicates under-expansion of the stent.
Post-dilation should be performed only with cautionwhen: 1) the valve is high (#4 mm below the annulus)
because regurgitation is more likely between the
uncovered cells and the risk of further migration
into the aorta is high; and 2) when there is bulky
calcium that may traumatize adjacent structures
(i.e., annulus, LV outﬂow tract/left bundle-branch
block, aorta) or threatens the coronary arteries.
Figure 9 shows an under-deployed valve resulting in
FIGURE 8 Transcatheter Valve–in–Transcatheter Valve Salvage for High (Aortic) Positioned Valve
A 92-year-old woman underwent transcatheter aortic valve replacement with a 26-mm valve. Although initial positioning by both trans-
esophageal echocardiography and ﬂuoroscopy was 4 to 5 mm below the annulus, the valve unexpectedly moved superiorly (A, red arrows),
resulting in the proximal end of the transcatheter heart valve within the aortic root (dotted red arrow). Color Doppler revealed severe
regurgitation (B, yellow arrows). A second valve was immediately deployed inferior (apical) to the ﬁrst valve (C) (solid blue arrow is the ﬁrst
valve and dotted blue arrow is the second valve); trace paravalvular regurgitation is seen (D, yellow arrows). (E) Final result is shown in the
ﬂuoroscopic image (solid blue arrow is the ﬁrst valve and dotted blue arrow is the second valve). The valve ﬁnal effective oriﬁce area was
1.5 cm2, with a peak and mean gradient of 19 mm Hg and 8 mm Hg, respectively.
FIGURE 9 Post-Dilation for Malapposition of the Transcatheter Stent
The patient has signiﬁcant paravalvular regurgitation (A, yellow arrow) as the result of incomplete expansion of the prosthesis, best seen on
3-dimensional color Doppler (B, yellow arrow) (Online Video 5). After post-dilation (C and D), there is obvious expansion of the prosthesis with
no paravalvular regurgitation seen.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 3 , 2 0 1 5 Hahn et al.
M A R C H 2 0 1 5 : 3 1 9 – 3 6 Imaging in Self-Expandable TAVR Complications
327
FIGURE 10 Ineffective Post-Dilation
Signiﬁcant paravalvular regurgitation (PAR) was seen immediately after transcatheter aortic valve replacement (TAVR) (A, yellow arrow) (Online
Video 6), and a post-dilation was performed. No change in the paravalvular regurgitation was seen with post-dilation (B) despite clear increase in
the expansion of the valve. In this case, the valve was implanted at the suggested depth of <6 mm from the annulus (C, blue arrows); however,
angulated color Doppler views (C) suggest that the jet is through the gaps in the lowest diamond cells, where there is no covering skirt (D, yellow
arrow). Three-dimensional color Doppler at the origin of the jets shows the regurgitation between the gaps in the valve frame (E, yellow arrows).
FIGURE 11 RV Perforation
An 89-year-old woman underwent valve implantation; her baseline imaging (A) shows no evidence for pericardial effusion. After transcatheter
aortic valve replacement (B), a new peri-aortic ﬂuid collection was noted (red arrow) and blood within the transverse pericardial ﬁssure was
suspected, consistent with possible chamber perforation. A circumferential hemopericardium slowly developed with hemodynamic instability.
An open surgical procedure conﬁrmed right ventricular (RV) perforation caused by a temporary pacemaker wire.
Hahn et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 3 , 2 0 1 5
Imaging in Self-Expandable TAVR Complications M A R C H 2 0 1 5 : 3 1 9 – 3 6
328
FIGURE 12 Ventricular Septal Perforation
In this 86-year-old woman, valve implantation was complicated immediately by membranous ventricular septal defect (VSD) (A, from the deep
gastric view, red arrow indicates the shunt) (Online Video 7). Hemodynamic instability ensued. An Impella was brieﬂy employed followed by
implant of an Amplatzer VSD occluder (B, transthoracic follow-up image; yellow arrow indicates the occluder device). Self-expanding valve
systolic and diastolic performance was not impaired given the supra-annular position of the transcatheter valve leaﬂets.
FIGURE 13 Aortic Wall Perforation With Peri-Aortic Hematoma
This patient had very severe calciﬁcation of the valve and implantation of a valve; during the implantation, a spicule of calcium is seen
expanding the wall of the aortic root (A, red arrow). An asymmetrically deployed valve is noted in the short-axis view. Color Doppler shows
severe, nearly circumferential paravalvular regurgitation (B, yellow arrows). A post-dilation was performed with resulting larger, more circular
valve (C) and trivial paravalvular regurgitation (yellow arrow). Within minutes, a peri-aortic hematoma (D, blue arrows) (Online Video 8) is seen
with protruding calcium (red asterisk) seen in the short-axis view. The patient was treated conservatively and remained intubated overnight
with blood pressure tightly controlled (systolic blood pressure, 100 to 120 mm Hg). Repeat transesophageal echocardiographic imaging the
following day showed slight resolution of the hematoma, and the patient was extubated and eventually discharged on post-operative day 6.
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330PAR, best seen on 3-dimensional (3D) color Doppler
(Online Video 5). Post-dilation for under-deployment,
particularly if the under-expansion is not due to
bulky calcium, is likely to be successful. Figure 10
(Online Video 6) is an example of ineffective post-
dilation in the setting of a high implantation; in this
example, the residual regurgitation is clearly identi-
ﬁed by both 2-dimensional and 3D imaging to arise
from between the lower half-diamond cells of the
nitinol frame.
The effect of a bicuspid valve (Figure 7) on
malpositioning, migration, and paravalvular regurgi-
tation continues to be studied. Two reports of TAVR
in a series of patients with bicuspid aortic valve haveFIGURE 14 Limitations of Transthoracic Imaging During Hemodynam
An 85-year-old woman with hypertension, hyperthyroidism, and normal
29-mm valve. Although there was some difﬁculty maneuvering the valv
positioned with the use of transthoracic imaging (B) and ﬂuoroscopic ima
as well as the curvature of the aorta forces the valve more anterior than
and the angiogram (D) showed acute type A aortic dissection from the a
inserted and conﬁrmed a dissection ﬂap (E, yellow arrow) with a large
the procedure was performed in a hybrid operating room, the procedure
Hemashield graft (Boston Scientiﬁc, Natick, Massachusetts) and a 23-mm
Minneapolis, Minnesota). The patient was discharged on post-operativeshown that compared with matched patients with
tri-leaﬂet aortic valve, there was no difference in
acute procedural success, valve hemodynamics, or
short-term survival (48,49). However, numerous case
reports of THV implantations in patients with
congenitally abnormal aortic valves (50–52) have
limited the use of TAVR in this population because of
reports of signiﬁcant aortic regurgitation or subopti-
mal ﬂow characteristics. A recent multicenter retro-
spective analysis of 139 patients receiving either the
balloon-expandable or self-expanding THV reported
a procedural mortality rate of 3.6%, with THV embo-
lization in 2.2% and conversion to surgery in 2.2%
(53). Thus, the procedural mortality rate is higheric Instability
coronaries underwent transcatheter aortic valve replacement with a
e around the aortic arch (A, red arrow), the valve was successfully
ging (C). Large bulky calcium in the left coronary cusp (C, blue arrow)
usual. When the valve was deployed, the patient became hypotensive
scending aorta to distal arch. A transesophageal probe was urgently
entrance site in the distal aortic arch (F, green arrow). Because
was converted to a full sternotomy with placement of a 30-mm
Mosaic bioprosthetic aortic valve replacement (Medtronic, Inc.,
day 8.
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331than prior reports of TAVR in tri-leaﬂet valves with
the balloon-expandable THV (0.9%), although THV
embolization and surgical conversion are comparable
(54). A higher incidence of PAR grade $2 is also re-
ported for bicuspid valves: 28.4% overall and 17.4%
when multislice computed tomography–based THV
sizing is used. There was no difference in PAR be-
tween self-expanding and balloon-expandable valves
(p ¼ 0.99). Sievers et al. (55) observed an increased
rate of post-implantation PAR in patients with
bicuspid aortic valve type 1 (single raphe) compared
with those with type 0 (no raphe): 34.2% versus 13.3%,
respectively (p ¼ 0.03). The authors postulate this
may be secondary to bulky calcium in the raphe (53).
VENTRICULAR PERFORATION
Patients with small LV cavities and hypercontractile
ventricles (such as elderly women) may be at partic-
ular risk for traumatic LV perforation from the stiff
wire or delivery sheath. The complication is oftenFIGURE 15 Transesophageal Echocardiography for Hemodynamic In
In this 92-year-old man, a successful valve implantation with conscious
several minutes later with a difference in arm-leg pressures: the femora
Emergent insertion of the transesophageal echocardiography probe conﬁ
frame (A, red arrow) to the renal arteries (B and C, red arrows).immediately apparent, with sudden hemodynamic
compromise along with paradoxical waveform
changes with respiration, and is easily conﬁrmed by
echocardiography. Right ventricular perforation has
also been reported, with transvenous pacing wire
most often implicated (Figure 11). The reported inci-
dence of tamponade after TAVR varies from 0% to
7% (56,57). Ventricular septal defects have also
been reported, particularly in the setting of a thin
membranous septum and ectopic bulky calcium
that may be seen extending from the aortic valve
into the LV outﬂow tract; deployment of the valve
or post-dilation may lead in displacement of the
calcium, resulting in traumatic disruption of the
septum. Figure 12 (Online Video 7) shows a large,
traumatic ventricular septal defect that resulted
in acute hemodynamic collapse requiring a ventricu-
lar support device. Given the supra-annular posi-
tion of the valve leaﬂets, a percutaneous closure
was performed with no compromise to valvular
function.stability
sedation and transthoracic echocardiographic imaging was followed
l artery pressure was much lower than the radial arterial pressure.
rmed an acute type A aortic dissection extending from the distal valve
FIGURE 16 Annula
This patient has bulk
of the pigtail in the
malapposition of the
Immediately after a p
with an aortic root r
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332LANDING ZONE TRAUMA
Aortic trauma can occur at any point in the deploy-
ment procedure, either from the catheters or the
valve or from displacement of bulky calciﬁc nod-
ules. Peri-aortic hematomas, ﬁrst described in the
setting of balloon-expandable implantation (58), may
also be seen with valve implantation (Figure 13,
Online Video 8). This complication arises from micro-
perforation of all 3 layers of the aortic root, with
a self-contained hematoma forming outside the
adventitia. Aortic dissections or intimal tears have
also been described during valve implantation. This
differs from peri-aortic hematomas because the
latter involves trauma to all 3 layers of the aortic
wall, whereas a dissection involves trauma to the
intimal layer. Aortic dissection may occur after
traumatic injury to the aorta by the valve deliveryr Rupture
y calciﬁcation of the right coronary cusp and sinus of Valsalva causing signiﬁc
right sinus of Valsalva during balloon aortic valvuloplasty (B, C, D) (Online V
edge of the valve (E) (blue arrow with faint blue ﬁgure indicates the position o
ost-dilation, a large pericardial effusion formed (F, orange arrow). An aortog
upture (G, yellow arrows) (Online Video 10) as well as residual signiﬁcant aosheath (Figure 14), particularly in the setting of an
unfolded and noncompliant aortic arch (59). Aortic
dissection also can be seen with unexpected high
implantation or migration of the THV (Figure 15). Both
peri-aortic hematoma and aortic dissection may be
localized and self-limiting if recognized early and can
be treated conservatively. Progression of either trau-
matic aortic complication may require open surgical
repair. Annular rupture, on the other hand, typically
requires open repair and has been reported with self-
expanding valve implantation in 0.6% to 0.9% of
cases (6,59). Figure 16 is an example of an aortic
annular rupture after TAVR. The patient’s risk factors
included a pre-implant BAV (Online Video 9), very
bulky calciﬁcation of the right coronary cusp and
sinus of Valsalva, and the need for post-dilation in
the setting of severe PAR. Immediately after a post-
dilation, a large pericardial effusion formed, and theant acoustic shadowing of the annulus (A) and prominent movement
ideo 9). Because of the bulky calciﬁcation, there was prominent
f the self-expanding valve) causing severe paravalvular regurgitation.
ram showed extravasation of dye into the peri-aortic space consistent
rtic regurgitation.
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333aortogram showed extravasation of dye into the peri-
aortic space (Online Video 10) consistent with an
aortic root rupture.
MITRAL VALVE REGURGITATION
Acute but reversible changes in mitral regurgitation
may also occur during TAVR. The main etiologies are
primary alteration in mitral morphology and second-
ary changes from ventricular dysfunction or dilation.
Figure 17 (Online Video 11) shows a poorly positioned
stiff wire that is wrapped around the chordae at the
base of the LV, resulting in signiﬁcant mitral regur-
gitation. The position of the wire is also suboptimal
for control of the introducing catheter and should be
repositioned. In the setting or wire entanglement, or
sometimes in the absence of obvious mitral apparatus
interaction, rupture of the chordae tendinae may
occur (Figure 18, Online Video 12). Although no clin-
ically signiﬁcant mitral regurgitation was identiﬁed in
this patient, ﬂail leaﬂets may occur, resulting in se-
vere mitral regurgitation.
CARDIOGENIC SHOCK
Many of the complications of TAVR can present with
cardiogenic shock because patients with signiﬁcant
systolic or diastolic dysfunction may not tolerateFIGURE 17 Wire Entanglement
Wire entanglement in the mitral chordae (Online Video 11) is seen
in this 3-dimensional image (dotted line indicates the course of
the wire), causing malcoaptation of the leaﬂet and resulting
severe mitral regurgitation.acute changes in hemodynamics. The development of
cardiogenic shock should prompt a rapid assessment
for: 1) signiﬁcant aortic or mitral regurgitation;
2) acute changes in ventricular function; 3) coronary
artery occlusion; 4) landing zone trauma or ventric-
ular perforation; and 5) pericardial effusion or tam-
ponade (Figure 19). Cardiogenic shock may also be
seen after rapid pacing (with intentional hypoten-
sion) in the setting of pre-existing ventricular
dysfunction or known coronary artery disease. The
resulting diffuse ischemia may resolve spontaneously
or require intravenous medications and immediate
implantation of the THV. Many operators no longer
perform a BAV before positioning and implantation of
the valve (17,18). Furthermore, hypotension of any
cause is usually poorly tolerated and should be
minimized through the use of volume expansion or
vasopressor support when necessary. Alternatively,
the direct administration of epinephrine into the LV
cavity with the use of a pigtail catheter can often be
an effective and rapid means of counteracting sudden
hypotension after valve implantation. Although a
short period of femoral cardiopulmonary support
might occasionally be necessary, in most cases,
relief of the transvalvular gradient with TAVR is
usually associated with immediate hemodynamic
improvement in the absence of any of the previously
described complications (1).FIGURE 18 Mitral Valve Trauma
An 86-year-old woman underwent valve implantation. The
mitral valve apparatus was structurally normal at baseline. After
transcatheter aortic valve replacement, a new mobile mass
within the submitral apparatus was identiﬁed from transgastric
imaging (arrow) (Online Video 12). Acute rupture of a secondary
chordae tendinae was suspected.
FIGURE 19 Echocardiography in Cardiogenic Shock
This 89-year-old man with a history of coronary artery disease (status post coronary artery bypass) had an ejection fraction of 20% and
signiﬁcant obstructive lung disease. The procedure was initiated under conscious sedation with transthoracic echocardiographic imaging, but,
just after the stiff wire was placed (A, red arrow), the patient became severely hypotensive and required emergency intubation and trans-
esophageal echocardiography probe placement. After conﬁrming the absence of ventricular perforation and tamponade but conﬁrmation of
poor systolic function (B), an emergency transcatheter aortic valve replacement was performed during intermittent chest compressions (C).
Severe paravalvular regurgitation (D, yellow arrows) was successfully treated with a post-dilation (E); however, the patient died 3 days later.
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334CONCLUSIONS
Numerous complications of TAVR can be imaged
with the use of intraprocedural echocardiography.
Patients must be carefully selected for the mini-
malist approach on the basis of the characte-
ristics of the patient (including risk of general
anesthesia), the aortic landing zone (including
risk of complications), and the experience of theoperators. TEE and certainly TTE add little risk
with signiﬁcant beneﬁts of early diagnosis of com-
plications and should remain an integral part of the
procedure.
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